Skip to content
stockresearch.app
EW/History

Edwards Lifesciences (EW) valuation history

Within its usual range

As of

EW's EV/EBITDA of 29.4x is lower than 67% of its available weekly readings from the last five years.

EV/EBITDA weekly history20.4×29.8×39.2×48.7×Shading: 5-year middle halfMedian 30.8×29.4×202120232025
Share EV/EBITDA history
Preview embed

Chart by stockresearch.app. Reuse with credit under CC BY 4.0.

EV/EBITDA at year-end

Last weekly reading of each completed year. Rank runs from lowest (0%) to highest (100%) within the five years available on that date.

EW year-end valuation history
Reading dateEV/EBITDA5-year rank
29.5×30%
32.2×33%
33.3×32%
25.1×4%
44.8×51%
59.5×100%
52.8×80%
26.8×51%
UnavailableShort history
UnavailableShort history

Loading related research…

About this history

What is EW's current EV/EBITDA?
EW's EV/EBITDA of 29.4x is lower than 67% of its available weekly readings from the last five years.
What is EW's five-year median EV/EBITDA?
The median, or middle weekly reading, is 30.8× over the last five years. Available history contains 533 weekly observations from Aug 8, 2016 to Oct 19, 2026.
Does a low historical rank mean a stock is a buy?
No. The rank describes a stock’s own history. Changes in growth, financial risk and the business can change the multiple investors pay. P/E uses earnings and P/S uses revenue from the previous twelve months.

Source: SEC company filings and weekly market prices. Multiples use the previous twelve months of financial results. Updated .

Read the valuation methodology